

## BIOGRAPHIES OF SPEAKERS

### MAIN SEMINAR

MONDAY, 21 NOVEMBER 2005

### CHAIR (MORNING)

RUTH, VISCOUNTESS RUNCIMAN

Dame Ruth Runciman chaired the Independent Inquiry into the UK's Misuse of Drugs Act. She was a member of the Statutory Advisory Council on the Misuse of drugs for twenty years. She currently chairs a National Health Service Trust which provides drug treatment services to a large area of London.

### CHAIR (AFTERNOON)

PROFESSOR COLIN BLAKEMORE  
Medical Research Council

Prof. Colin Blakemore is the Chief Executive of the Medical Research Council (MRC), the Waynflete Chair of Physiology, University of Oxford, and Director of the Oxford Centre for Cognitive Neuroscience. He has also been President and Chairman of the British Association for the Advancement of Science. He has won numerous prizes and medals from medical and scientific academies and societies including the Royal Society Michael Faraday Prize for furtherance of the public understanding of science. He has been President and Chairman of the British Association for the Advancement of Science, President of the British Neuroscience Association, and of the Physiological Society and the Biosciences Federation. He is a frequent broadcaster on TV and radio, a Reith lecturer, and he has published numerous books and academic articles.

### DOCTOR MARCUS ROBERTS MIND

Marcus Roberts is Head of the Policy and Parliamentary Unit at Mind, the mental health charity. From 2002 to September 2005, he was Head of Policy at DrugScope, and a key author of Beckley reports and briefings. Before working at DrugScope he was senior policy adviser at Nacro, the crime reduction charity. He edited the journal *Childright* from 1998 to 2000 and the magazine *Safer Society* from 2000 to 2002. In 1994 he was Baring Foundation Fellow in Human Rights at the University of Essex, and subsequently taught in the Philosophy Department at Essex for three years, working closely with the Human Rights Centre. He has published numerous policy reports, articles and briefings on a wide range of social policy issues.

PROFESSOR FRANCISCO THOUMI  
UNIVERSIDAD DEL ROSARIO

Francisco Thoumi is currently a Professor of Economics and the Director of the Research and Monitoring Centre on Drugs and Crime, Universidad del Rosario, Bogotá, Colombia. He is also a member of the Board of Directors of the Colombian Economics Academy.

From August 1999 to September 2000, he was the research coordinator for the Global Program against Money Laundering, United Nations Office of Drug Control and Crime Prevention. He was the regional coordinator for the United Nations research program on the economic effects of the illegal drug industry in Bolivia, Colombia and Peru from 1993-1996.

He has authored numerous books, over 45 book chapters and 90 academic journal articles on the subject of illegal drugs.

DOCTOR ALEX STEVENS  
EUROPEAN INSTITUTE OF SOCIAL SERVICES

Alex Stevens works for the European Institute of Social Services at the University of Kent. He is the principal author of the Beckley Foundation report (number 5) on Reducing Drug-Related Crime. He currently leads QCT Europe, a six-country research project on treatment for drug dependent offenders. He has a long-standing interest in drugs, crime and the penal systems of Europe. Before joining EISS in 1998, Alex managed the European Network of Drug and HIV/AIDS Services in Prison at Cranstoun Drug Services.

PROFESSOR MARK KLEIMAN  
UCLA

Mark A. R. Kleiman is Professor of Public Policy and Director of the Drug Policy Analysis Program in the School of Public Affairs at UCLA. His research focuses on drug policy and crime control, and he is widely identified with the proposal to institute frequent drug testing and automatic sanctions for drug use for drug-involved offenders on probation and parole.

Prof. Kleiman is also the editor of the Drug Policy Analysis Bulletin and the Chairman of BOTEK Analysis Corporation, which provides policy advice to governments at all levels on the issues of drug, crime and health. He is the author of two books, and is currently working on a third. He also publishes a weblog at <http://www.markarkleiman.com>.

In addition to his academic work, Prof. Kleiman serves as a policy adviser on drug problems to various government entities. He has recently published a report for the Congressional Research Service on the link between terrorism and the illicit drug trade.

Before joining UCLA, Prof. Kleiman taught at Harvard's Kennedy School of Government, where he received his Ph.D. in Public Policy. From 1979-1983, he served in the Office of Policy and Management Analysis of the Criminal Division of the United States Department of Justice, first as Deputy Director for Drug Control Programs and then as Acting Director and Director.

PROFESSOR GERRY STIMSON  
INTERNATIONAL HARM REDUCTION ASSOCIATION  
& IMPERIAL COLLEGE LONDON

Gerry Stimson, PhD, is Executive Director of the International Harm Reduction Association. IHRA is a global advocacy organisation which promotes a harm reduction approach to the use of legal and illegal psychoactive drugs. He is also Emeritus Professor of Sociology at Imperial College London.

He has nearly 40 years of research on drug and alcohol issues. He directed the Centre for Research on Drugs and Health Behaviour from 1990 until 2004, with a programme of research on reducing harms from drug and alcohol use including the evaluation of methadone and heroin prescribing, syringe exchange, surveillance of HIV and other blood borne infections, drugs in prisons, and prevalence of drug use.

He has over 200 academic publications. He has advised the UK government, the World Health Organization, UNAIDS, and the United Nations Office on Drugs and Crime, on drugs and HIV/AIDS. He is editor-in-chief of the International Journal of Drug Policy.

DOCTOR ANINDYA CHATTERJEE  
JOINT UNITED NATIONS PROGRAMME ON HIV/AIDS (UNAIDS)

Anindya Chatterjee has provided leadership in policy and programme development in the area of health, development, drug control and HIV/AIDS over the last two decades. He has worked with the United Nations, government authorities, NGOs, research and international agencies. He has lived and worked in Bangladesh, India, Iran, Myanmar, Nepal, Switzerland, Thailand, USA and has been closely involved with national HIV/AIDS, health, development and drug control programmes in several countries of the world.

He currently coordinates the prevention team of the Joint United Nations Programme on HIV/AIDS (UNAIDS) based in Geneva. His specific areas of expertise include development of HIV prevention and care programmes for vulnerable populations, HIV situation analyses, public policy research and advocacy. He also has extensive experience in training different civil society and other groups in various aspects of health care. He has helped pioneer health and development programmes for poor and marginalized populations, developed several pioneering outreach and needle-exchange programmes within Asia, developed guidelines for rapid assessment surveys and founded a mental health NGO in India. He has authored several articles and books. A recently edited book entitled 'Living with the AIDS virus: the epidemic and the response in India' has been published in India.

He graduated in medicine in 1983 and subsequently obtained doctoral degree in psychiatry and post-doctoral training in anthropology and public health in India and US.

PROFESSOR LESLIE IVERSEN  
UNIVERSITY OF OXFORD

Leslie Iversen PhD is a Visiting Professor at the Department of Pharmacology, University of Oxford. He directed the Wolfson Centre for Research on Age Related Diseases at Kings College London (1999-2004), and was previously Director of the Neuroscience Research Centre set up by the international pharmaceutical company Merck & Co Inc in Harlow, Essex, UK (1983-1995), and Director of the UK Medical Research Council Neurochemical Pharmacology Unit in Cambridge, England (1970-1983). He is interested in understanding how drugs work in the nervous system and in the molecular basis of nervous system disorders and is particularly known for his work on the chemical messengers used for communication between nerve cells. He is the author of several books and of more than 350 scientific publications and is a Fellow of the Royal Society of London and a Foreign Associate of the National Academy of Sciences, USA. He acted as the specialist adviser to the House of Lords Science & Technology Committee's enquiry into Cannabis, 1998, and is currently a member of the Home Office Advisory Council on the Misuse of Drugs. His most recent books are "Speed, Ecstasy, Ritalin: Use and Abuse of Amphetamine", Oxford University Press, 2006; "A Very Short Introduction to Drugs", Oxford University Press, 2001; and "The Science of Marijuana", Oxford University Press, 2000.

ROB KAMPIA  
MARIJUANA POLICY PROJECT

Rob Kambia is co-founder and executive director of the Marijuana Policy Project (MPP), the largest non-profit organization in the U.S. that is solely dedicated to ending marijuana prohibition (with an emphasis on removing criminal penalties for the medical use of marijuana). MPP has established itself as the leading organization to call for the repeal of marijuana prohibition in Congress.

Kampia helped draft most of the medical marijuana laws that have been enacted in ten states, and has testified before legislative committees in California, Maine, Maryland, Massachusetts, Nevada, Ohio, Vermont, and Washington state. In March 2001, Kambia testified before a subcommittee of the U.S. House of Representatives on the medical marijuana case that was pending before the U.S. Supreme Court at the time.

PROFESSOR DAVID E. NICHOLS  
PURDUE UNIVERSITY

Professor David E. Nichols, Ph.D., is Professor of Medicinal Chemistry and Molecular Pharmacology at the Purdue University School of Pharmacy and Pharmaceutical Sciences in West Lafayette, Indiana. He is also an Adjunct Professor of Pharmacology and Toxicology at the Indiana University School of Medicine. His unique research spans a continuum, from computer-assisted drug design and chemical synthesis, to in vitro and animal pharmacology, giving him a very broad perspective on biomedical research that is quite unusual.

He has published more than 250 scientific papers and book chapters, is the holder of seven U.S. patents, and has been an invited speaker at numerous national and international symposia. His research has been continuously funded by the NIH for nearly three decades. He has served on numerous governmental study sections, advisory boards, and review panels, and serves as a consultant to the pharmaceutical industry. He was named a fellow of the American Pharmaceutical Association, a fellow of the American Association of Pharmaceutical Scientists, and was elected to membership in the American College of Neuropsychopharmacology. In 2004 he was named the Irwin H. Page Lecturer by the International Serotonin Club.

Professor Nichols has been studying hallucinogenic drugs since 1969, and is considered by many scientists to be the world's top authority on the chemistry and pharmacology of these substances. He is also the founding president of the Heffter Research Institute, a not-for-profit organization incorporated in 1993 to encourage and support rigorous scientific studies of the medical potential of psychedelic agents. In addition to his work on hallucinogens, he also has been a world leader in the research of novel dopamine D1 agonists to treat Parkinson's disease, and to treat the cognitive and memory deficits of schizophrenia. He was the scientific cofounder of a small biotech company to commercialize these therapeutic agents, which are now in Phase II clinical studies.

DOCTOR JOHN MARSDEN  
INSTITUTE OF PSYCHIATRY

John Marsden Ph.D. is a chartered clinical research psychologist and senior lecturer in addictive behaviour at the Division of Psychological Medicine, Institute of Psychiatry, King's College London. He is a member of the Advisory Council on the Misuse of Drugs and Regional Editor for Europe, Asia and Africa for the journal *Addiction*. John has research interests in treatment evaluation with a current focus on cocaine (in the U.K) and methamphetamine (in the Asia Pacific region).



THE BECKLEY/FORESIGHT SEMINAR  
ON FUTURE POLICY CHALLENGES  
TUESDAY, 22 NOVEMBER 2005

CHAIR  
LORD LAYARD

Richard Layard was founder-director of the LSE Centre for Economic Performance, a large research centre covering most areas of economic policy. Since 2000 he has been a member of the House of Lords. He has written widely on unemployment, inflation, education, inequality and post-Communist reform. He was an early advocate of the welfare-to-work approach to unemployment, and co-authored the influential book "*Unemployment: Macroeconomic Performance and the Labour Market*" (OUP 1991). He was Chairman of the European Commission's Macroeconomic Policy Group in the 1980s and then co-Chairman of the World Economy Group set up by WIDER. From 1991-97 he was an economic adviser to the Russian government's economic staff. His current research interest focuses on happiness, aiming to achieve a unified understanding of the insights of economics, psychology, neuroscience and philosophy.

ANDREW JACKSON  
FORESIGHT, OFFICE OF SCIENCE AND TECHNOLOGY

Andrew is Deputy Director of the Foresight programme at the Office of Science and Technology. He has overseen a number of the recent Foresight projects, covering topics such as, Cognitive Systems, Flood and Coastal Defence, Intelligent Infrastructure and Brain Science, Addiction and Drugs. Before taking up his current post, Andrew has worked in the DTI across a broad range of areas, including European Union policy, government department legislation and finance.

PROFESSOR DAVID NUTT  
UNIVERSITY OF BRISTOL

David Nutt (DM, FRCP, FRCPsych, FMedSci) is currently Professor of Psychopharmacology and Head of the Department of Community Based Medicine at the University of Bristol.

He received his undergraduate training in medicine at Cambridge and Guy's Hospital, and continued training in neurology to MRCP. After completing his psychiatric training in Oxford, he continued there as a lecturer and then later as a Wellcome Senior Fellow in psychiatry. He then spent two years as Chief of the Section of Clinical Science in the National Institute of Alcohol Abuse and Alcoholism in NIH, Bethesda, USA. On returning to England in 1988 he set up the Psychopharmacology Unit in Bristol, an interdisciplinary research grouping spanning the departments of Psychiatry and Pharmacology. Their main research interests are in the brain mechanisms underlying anxiety, depression and addiction and the mode of action of therapeutic drugs.

He is currently a member of the Advisory Council on the Misuse of Drugs (ACMD), and Chair of its Technical Committee, a member of the Committee on Safety of Medicines (CSM), on the Council and President-Elect of the European College of Neuropsychopharmacology (ECNP) and a Director of the 'European Certificate in Anxiety and Mood Disorders' and the 'Masters in Affective Disorders' Courses jointly administered by the Universities of Maastricht, Bristol and Florence. In addition, he is the Editor of the Journal of Psychopharmacology, advisor to the British National Formulary and a Past-President of the British Association of Psychopharmacology (BAP). He was also a member of the Independent Inquiry into the Misuse of Drugs Act 1971, chaired by Viscountess Runciman that reported in 2000.

PROFESSOR PETER REUTER  
UNIVERSITY OF MARYLAND

Peter Reuter is Professor in the School of Public Policy and in the Department of Criminology at the University of Maryland. From 1999 to 2004 he was editor of the *Journal of Policy Analysis and Management*. He is Director of the newly formed Center on the Economics of Crime and Justice Policy at the University.

From 1981 to 1993 he was a Senior Economist in the Washington office of the RAND Corporation. He founded and directed RAND's Drug Policy Research Center from 1989-1993; the Center is a multi-disciplinary research program begun in 1989 with funding from a number of foundations. His early research focused on the organization of illegal markets and resulted in the publication of *Disorganized Crime: The Economics of the Visible Hand* (MIT Press, 1983), which won the Leslie Wilkins award as most outstanding book of the year in criminology and criminal justice. Since 1985 most of his research has dealt with alternative approaches to controlling drug problems, both in the United States and Western Europe. His other books are (with Robert MacCoun) *Drug War Heresies: Learning from Other Places, Times and Vices* (Cambridge University Press, 2001) and (with Edwin Truman) *Chasing Dirty Money: The Fight Against Money Laundering* (Institute for International Economics, 2004). He is currently directing a project on global heroin markets.

Dr. Reuter was a member of the National Research Council Committee on Law and Justice from 1997-2002 and of the Office of National Drug Control Policy's Committee on Data, Research and Evaluation from 1996-2003. He served on the Institute of Medicine Committee on the Federal Regulation of Methadone (1992-1994) and the IOM panel on Assessing the Scientific Base for Reducing Tobacco-Related Harm (2000). The Attorney General appointed him as one of five non-governmental members of the Interagency Task Force on Methamphetamine in 1997. He has testified frequently before Congress and has addressed senior policy audiences in many countries, including Australia, Chile, Colombia and Great Britain. He has served as a consultant to numerous government agencies (including GAO, ONDCP, NIJ, SAMHSA) and to foreign organizations including the European Monitoring Center on Drugs and Drug Abuse, United Nations Drug Control Program and the British Department of Health. Dr. Reuter received his PhD in Economics from Yale.

PROFESSOR ROBERT MACCOUN  
UNIVERSITY OF CALIFORNIA AT BERKELEY

Robert MacCoun is Professor of Public Policy, Professor of Law, and Affiliated Professor of Psychology at the University of California at Berkeley. Prior to joining the Berkeley faculty, from 1986-1993 he was a behavioral scientist at RAND, a non-profit policy research organization.

MacCoun has collaborated with economist Peter Reuter on studies of street-level drug dealing in Washington, DC., comparative research on European and American drug policies, and analyses of the effects of drug laws on drug use and drug-related harms. Their book, *Drug War Heresies: Learning from Other Vices, Times, and Places*, was published in August 2001 by Cambridge University Press. MacCoun has also conducted numerous studies of jury decision-making, civil litigation, and bias in the interpretation of research results, and he is a coauthor of RAND's 1993 study of the effects of sexual orientation on military performance. His articles have appeared in *Science*, *Psychological Review*, *American Psychologist*, *Annual Review of Psychology*, *The Nation*, and various legal and social science journals. In 1996 he was selected as Distinguished Wellness Lecturer by the California Wellness Foundation and the University of California. In 1999, he was a Visiting Professor at the Woodrow Wilson School at Princeton University.

PROFESSOR TREVOR ROBBINS  
UNIVERSITY OF CAMBRIDGE

Trevor Robbins was appointed in 1997 as the Professor of Cognitive Neuroscience at the University of Cambridge. He was elected to the Chair of Expt. Psychology (and Head of Department) at Cambridge from October 2002. He is also Director of the newly-established Cambridge MRC-Wellcome Trust Behavioural and Clinical Neuroscience Institute, the main objective of which is to inter-relate basic and clinical research in Psychiatry and Neurology for such conditions as Parkinson's, Huntington's, and Alzheimer's diseases, frontal lobe injury, schizophrenia, depression, drug addiction and developmental syndromes such as attention deficit/hyperactivity disorder.

Trevor has been President of the European Behavioural Pharmacology Society (1992-1994) and he won that Society's inaugural Distinguished Achievement Award in 2001. He was also President of the British Association of Psychopharmacology from 1996 to 1997. Other awards include a medal at the College de France and the IPSEN Foundation medal for outstanding research. He has edited the journal *Psychopharmacology* since 1980 and joined the editorial board of *Science* in Jan. 2003. He is a Fellow of the British Psychological Society and of the Academy of Medical Sciences. He has been a member of the Medical Research Council (UK) and chaired the Neuroscience and Mental Health Board from 1995 until 1999. He has been included on a list of the 100 most cited neuroscientists by ISI. He has published about five hundred full papers in scientific journals or chapters and has co-edited three books (*Psychology for Medicine: The Prefrontal Cortex; Executive and Cognitive Function*, and *Disorders of Brain and Mind*). He has been elected (May 2005) as a Fellow of the Royal Society and recently gave the Fred Kavli Distinguished International Scientist Lecture at the Society for Neuroscience Annual Meeting, in Washington D.C.

PROFESSOR BARBARA J. SAHAKIAN  
UNIVERSITY OF CAMBRIDGE

Barbara J Sahakian is Professor of Clinical Neuropsychology at the Department of Psychiatry, School of Clinical Medicine, University of Cambridge. She obtained her BA (Magna cum Laude) from Mount Holyoke College, her PhD from the University of Cambridge (Darwin College) and her Dip Clin Psych from the British Psychological Society. She held postdoctoral positions at the Massachusetts Institute of Technology (MIT, Cambridge, USA) and the Institute of Neurology (Queen Square, London). Before taking up her academic post at the University of Cambridge, she was a Lecturer and a Senior Lecturer in the Department of Psychiatry, Institute of Psychiatry (London). Her research interests include neuropsychology, neuropsychiatry, neuroimaging and cognitive psychopharmacology.

Professor Sahakian has over 185 publications in scientific journals including *Nature*, *Science*, *The Lancet*, *British Medical Journal*, *Archives of General Psychiatry*, *The Journal of Neuroscience*, *Brain*, *Psychopharmacology* and *Psychological Medicine*.

She is also co-inventor of the CANTAB computerised neuropsychological tests, which are in growing use world-wide. Professor Sahakian is a Fellow of Clare Hall, where she chairs the Visiting Fellowships and Research Fellowships Committee, and a Bye-Fellow of Christ's College, where she is Director of Studies in Experimental Psychology. She has held the F.C. Donders Visiting Chair in Psychopharmacology at Utrecht University, Netherlands in 2004-5, is a Fellow of the Academy of Medical Sciences and will shortly be joining the MRC Neuroscience and Mental Health Board.

PROFESSOR ALASTAIR CAMPBELL  
UNIVERSITY OF BRISTOL

Alastair Campbell is Professor Emeritus of Ethics in Medicine in the School of Medicine, University of Bristol and Director of the Centre for Ethics in Medicine. He is a former President of the International Association of Bioethics. Recent publications include *Health as Liberation* (Pilgrim Press, 1995) and *Medical Ethics, 4th Edition*, co-authored with Grant Gillett and Gareth Jones (Oxford University Press, 2005). Professor Campbell is a member of the Medical Ethics Committee of the British Medical Association. Until recently, Professor Campbell was Chairman of the Wellcome Trust's Standing Advisory Group on Ethics and Vice-chairman of the Retained Organs Commission. He is currently Chairman of the UK Biobank's Ethics and Governance Council.

DOCTOR CHARLES R. SCHUSTER  
WAYNE STATE SCHOOL OF MEDICINE

Charles R. Schuster, PhD, is an internationally recognized researcher on the psychopharmacology of drugs of abuse. From 1986 – 1992, Dr. Schuster served as the Director of the National Institute on Drug Abuse (NIDA). In January 1992, Dr. Schuster returned to his research career as a Senior Research Scientist at the Addiction Research Center of the NIDA. In January 1995, Dr. Schuster was appointed as a Professor in the Department of Psychiatry and Behavioral Neurosciences at Wayne State University School of Medicine and the Director of the Clinical Research Division on Substance Abuse. In September 2000, he assumed the position of Director of the Great Lakes Regional Node of the NIDA Clinical Trials Network. Prior to joining the National

Institute on Drug Abuse (NIDA) in 1986, Dr. Schuster was the Director of the University of Chicago's Drug Abuse Research Center, and Professor of Psychiatry, Pharmacology and Behavioral Science. He has authored or co-authored over 200 scientific journal articles, as well as numerous book chapters and several books. He has served on the FDA Drug Abuse Advisory Committee and is also a member of the Expert Advisory Panel on Drug Dependence of the World Health Organization.

Dr. Schuster's primary research interests include the development of medications and behavioral interventions for the treatment of tobacco, cocaine, amphetamine and heroin dependence; the laboratory evaluation of new medications for their abuse potential; post-marketing surveillance of diversion and abuse of new psychotropic medications; and the role of co-morbid psychiatric disorders in the etiology and maintenance of drug dependence. Dr. Schuster has been active in numerous professional organizations and has been the recipient of many awards.